ArticleFrontiers in cardiovascular medicine2026
A nomogram integrating CTPA parameters and serum biomarkers to predict 30-day mortality and refine risk stratification in non-high-risk acute pulmonary embolism.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the predictive value of CT pulmonary angiography (CTPA) imaging parameters combined with serum biomarkers for 30-d all-cause mortality in non-high-risk acute pulmonary embolism (APE), and to compare parameters between simplified Pulmonary Embolism Severity Index (sPESI)-based risk strata. Methods: This retrospective study enrolled 250 first-episode non-high-risk APE patients (50 deaths, 200 survivors). CTPA-derived pulmonary artery obstruction index (PAOI), right/left ventricular diameter ratio (RV/LV), main pulmonary/ascending aorta ratio, and serum biomarkers high-sensitivity cardiac troponin I (hs-cTnI), brain natriuretic peptide (BNP), D-dimer, and blood lactate (BLa) were collected. Independent risk factors were identified using Firth penalized likelihood logistic regression to construct a nomogram, which was internally validated. The incremental predictive value over sPESI was quantified. Cox regression was used to assess prognostic values and interactions. Spearman correlation analysis was conducted for relationships between imaging and biomarkers. Patients were stratified by sPESI into intermediate-risk (≥ 1 point) and low-risk (0 points) groups for comparative and survival analyses. Results: Death Conclusion: The nomogram incorporating syncope, SBP <100 mmHg, RV/LV, BNP, and BLa, is an effective tool for predicting 30-day mortality in non-high-risk APE patients, demonstrating superior performance over sPESI. Combining CTPA imaging and serum biomarkers offers independent and complementary prognostic information, enhancing risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.